Market Cap 10.92B
Revenue (ttm) 1.19B
Net Income (ttm) 14.01M
EPS (ttm) N/A
PE Ratio 77.21
Forward PE 74.30
Profit Margin 1.17%
Debt to Equity Ratio 0.00
Volume 458,600
Avg Vol 431,534
Day's Range N/A - N/A
Shares Out 39.16M
Stochastic %K 94%
Beta 0.51
Analysts Strong Sell
Price Target $311.94

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under...

Industry: Medical Devices
Sector: Healthcare
Phone: 510 748 3200
Address:
One Penumbra Place, Alameda, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:22 AM
$PEN is currently trading at $280.07, showing a strong upward momentum with an RSI of 66.39, indicating it is nearing overbought territory but still has room for further gains. The price is significantly above the 30-day moving average (MA30) of 252.9 and the 50-day moving average (MA50) of 256.09, suggesting a bullish trend. The recent high of $288.91 within the last 60 days provides a key resistance level to watch. For a trade plan, consider entering a long position at $280.50, just above the current close to confirm upward momentum. Set a stop loss at $268.49, slightly below the MA30, to manage risk. Target 1 can be set at $288.00, near the 60D high, and Target 2 at $295.00, allowing for potential further upside if momentum continues. Overall, the analysis indicates a bullish bias for $PEN based on current metrics. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:56 AM
$PEN is currently trading at $278.74, above its 30-day moving average (MA30) of $252.1 and its 50-day moving average (MA50) of $256.12, indicating a bullish trend. The RSI at 62.68 suggests that the stock is nearing overbought territory, but not yet in it, allowing for potential upward movement. The recent high of $288.91 provides a resistance level, while the low of $221.26 offers support. Trade Plan: - Directional Bias: Bullish, given the position above MAs and the RSI level. - Suggested Entry: $280.00, to capitalize on momentum. - Stop: $270.00, to limit potential losses below recent support. - Target 1: $288.00, approaching the 60D high. - Target 2: $295.00, for a more aggressive profit-taking point. Monitor for any changes in RSI and price action near targets. https://privateprofiteers.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 3:37 PM
$PEN Share Price: $275.74 Contract Selected: Apr 17, 2026 $280 Calls Buy Zone: $18.79 – $23.21 Target Zone: $35.66 – $43.59 Potential Upside: 79% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:02 AM
$PEN is currently trading at $279.67, showing a strong upward momentum as indicated by an RSI of 63.63, which suggests it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of $250.23 and the 50-day moving average (MA50) of $255.93, reinforcing a bullish trend. The recent 60-day high of $288.91 provides a key resistance level, while the 60-day low of $221.26 establishes a solid support range. For a trade plan, consider entering at $280.00, with a stop loss set at $267.00 to manage risk. Target 1 can be set at $288.00, just below the recent high, while Target 2 can be set at $295.00, allowing for potential breakout gains. This strategy capitalizes on the current bullish momentum while maintaining a disciplined risk management approach. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:38 AM
$PEN is currently trading at $279.67, showing a strong upward momentum as indicated by an RSI of 63.63, which suggests it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of $250.23 and the 50-day moving average (MA50) of $255.93, reinforcing a bullish trend. The recent 60-day high of $288.91 provides a key resistance level, while the 60-day low of $221.26 establishes a solid support range. For a trade plan, consider entering at $280.00, with a stop loss set at $267.00 to manage risk. Target 1 can be set at $288.00, just below the recent high, while Target 2 can be set at $295.00, allowing for potential breakout gains. This strategy capitalizes on the current bullish momentum while maintaining a disciplined risk management approach. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 1:57 PM
$PEN keeps climbing! 🚀 Q3 adjusted EPS of 97 cents beat estimates by 7.78%, and revenues surged 17.8% year over year on a reported basis, propelling the stock up 20% since the announcement on Nov. 5. Impressive margin expansions and strong product sales are driving the momentum. 📈 Discover the full story here 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-body-20424&ADID=SYND_STOCKTWITS_TWEET_2_2789089_BODY_20424
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 12:57 PM
$PEN surges after strong Q3 beat 🔥 Earnings and revenue both topped estimates, and the company’s margins expanded — signaling solid operational strength this quarter. See what’s driving the move higher 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-teaser-20404&ADID=SYND_STOCKTWITS_TWEET_2_2789089_TEASER_20404
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:47 PM
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 8 at 3:50 PM
$PEN Penumbra jumps after Q3 2025 earnings beat; $355 M revenue and $1.17 EPS spark stronger 2026 forecasts. Click here to learn more! https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 10:01 PM
JP Morgan has updated their rating for Penumbra ( $PEN ) to Overweight with a price target of 275.
0 · Reply
Latest News on PEN
Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:31 PM EST - 9 days ago

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript


Penumbra, Inc. Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 9 days ago

Penumbra, Inc. Reports Third Quarter 2025 Financial Results


Penumbra, Inc. Names Shruthi Narayan as Company President

Aug 27, 2025, 9:00 AM EDT - 2 months ago

Penumbra, Inc. Names Shruthi Narayan as Company President


Penumbra, Inc. to Present at Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 3 months ago

Penumbra, Inc. to Present at Upcoming Investor Conferences


Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 9:04 PM EDT - 3 months ago

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript


Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 4:05 PM EDT - 3 months ago

Penumbra, Inc. Reports Second Quarter 2025 Financial Results


Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Apr 23, 2025, 8:15 PM EDT - 7 months ago

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript


Penumbra, Inc. Reports First Quarter 2025 Financial Results

Apr 23, 2025, 4:05 PM EDT - 7 months ago

Penumbra, Inc. Reports First Quarter 2025 Financial Results


Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 11:04 PM EST - 9 months ago

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript


Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 11:45 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript


Penumbra, Inc. Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Reports Third Quarter 2024 Financial Results


Penumbra, Inc. (PEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 7:25 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q2 2024 Earnings Call Transcript


Penumbra, Inc. Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Reports Second Quarter 2024 Financial Results


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:22 AM
$PEN is currently trading at $280.07, showing a strong upward momentum with an RSI of 66.39, indicating it is nearing overbought territory but still has room for further gains. The price is significantly above the 30-day moving average (MA30) of 252.9 and the 50-day moving average (MA50) of 256.09, suggesting a bullish trend. The recent high of $288.91 within the last 60 days provides a key resistance level to watch. For a trade plan, consider entering a long position at $280.50, just above the current close to confirm upward momentum. Set a stop loss at $268.49, slightly below the MA30, to manage risk. Target 1 can be set at $288.00, near the 60D high, and Target 2 at $295.00, allowing for potential further upside if momentum continues. Overall, the analysis indicates a bullish bias for $PEN based on current metrics. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:56 AM
$PEN is currently trading at $278.74, above its 30-day moving average (MA30) of $252.1 and its 50-day moving average (MA50) of $256.12, indicating a bullish trend. The RSI at 62.68 suggests that the stock is nearing overbought territory, but not yet in it, allowing for potential upward movement. The recent high of $288.91 provides a resistance level, while the low of $221.26 offers support. Trade Plan: - Directional Bias: Bullish, given the position above MAs and the RSI level. - Suggested Entry: $280.00, to capitalize on momentum. - Stop: $270.00, to limit potential losses below recent support. - Target 1: $288.00, approaching the 60D high. - Target 2: $295.00, for a more aggressive profit-taking point. Monitor for any changes in RSI and price action near targets. https://privateprofiteers.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 3:37 PM
$PEN Share Price: $275.74 Contract Selected: Apr 17, 2026 $280 Calls Buy Zone: $18.79 – $23.21 Target Zone: $35.66 – $43.59 Potential Upside: 79% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:02 AM
$PEN is currently trading at $279.67, showing a strong upward momentum as indicated by an RSI of 63.63, which suggests it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of $250.23 and the 50-day moving average (MA50) of $255.93, reinforcing a bullish trend. The recent 60-day high of $288.91 provides a key resistance level, while the 60-day low of $221.26 establishes a solid support range. For a trade plan, consider entering at $280.00, with a stop loss set at $267.00 to manage risk. Target 1 can be set at $288.00, just below the recent high, while Target 2 can be set at $295.00, allowing for potential breakout gains. This strategy capitalizes on the current bullish momentum while maintaining a disciplined risk management approach. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:38 AM
$PEN is currently trading at $279.67, showing a strong upward momentum as indicated by an RSI of 63.63, which suggests it is nearing overbought territory but still has room for further gains. The price is above both the 30-day moving average (MA30) of $250.23 and the 50-day moving average (MA50) of $255.93, reinforcing a bullish trend. The recent 60-day high of $288.91 provides a key resistance level, while the 60-day low of $221.26 establishes a solid support range. For a trade plan, consider entering at $280.00, with a stop loss set at $267.00 to manage risk. Target 1 can be set at $288.00, just below the recent high, while Target 2 can be set at $295.00, allowing for potential breakout gains. This strategy capitalizes on the current bullish momentum while maintaining a disciplined risk management approach. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 1:57 PM
$PEN keeps climbing! 🚀 Q3 adjusted EPS of 97 cents beat estimates by 7.78%, and revenues surged 17.8% year over year on a reported basis, propelling the stock up 20% since the announcement on Nov. 5. Impressive margin expansions and strong product sales are driving the momentum. 📈 Discover the full story here 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-body-20424&ADID=SYND_STOCKTWITS_TWEET_2_2789089_BODY_20424
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 12:57 PM
$PEN surges after strong Q3 beat 🔥 Earnings and revenue both topped estimates, and the company’s margins expanded — signaling solid operational strength this quarter. See what’s driving the move higher 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-teaser-20404&ADID=SYND_STOCKTWITS_TWEET_2_2789089_TEASER_20404
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:47 PM
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 8 at 3:50 PM
$PEN Penumbra jumps after Q3 2025 earnings beat; $355 M revenue and $1.17 EPS spark stronger 2026 forecasts. Click here to learn more! https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 10:01 PM
JP Morgan has updated their rating for Penumbra ( $PEN ) to Overweight with a price target of 275.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 8:09 PM
Canaccord Genuity has adjusted their stance on Penumbra ( $PEN ), setting the rating to Buy with a target price of 350 → 355.
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:41 PM
$PEN Buy Jefferies raises target price to $335 from $325 JP Morgan raises target price to $275 from $265 Truist Securities raises target price to $312 from $300
0 · Reply
RenHenInvestments
RenHenInvestments Nov. 6 at 12:11 PM
$PEN Solid results, nice gap fill.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 6 at 12:05 PM
WATCHLIST NOV 06 2025 $XOM Exxon Mobil Expects First Gas From Offshore Greece Project Between 2030 And 2035 With Investment Of $50M To $100M $SLSR Solaris Resources Announce The Results Of A Pre-feasibility Study With An Updated Mineral Resource Estimate And Maiden Mineral Reserves For Its Warintza Project, Located In Southeastern Ecuador $PEN Penumbra shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates. $LTRX Needham Maintains Buy on Lantronix, Raises Price Target to $7.5 $LLY Eli Lilly' Phase 2 Trial For Obesity With At Least One Obesity-related Comorbidity And Without Type 2 Diabetes, Showed At 48 Weeks, All Treatment Arms Of Eloralintide Met The Primary Endpoint, Demonstrating Superior Mean Weight Reductions From 9.5% To 20.1% Compared To Placebo
0 · Reply
theflynews
theflynews Nov. 6 at 1:59 AM
Closing Bell Movers: Qualcomm down 3%, Robinhood slips 2% on earnings - $PEN - https://thefly.com/permalinks/entry.php/PENid4232011?1762393
0 · Reply
Nurse007
Nurse007 Nov. 5 at 9:55 PM
$PEN didn’t buy enough before the bell
0 · Reply
healthcareguru
healthcareguru Nov. 5 at 9:21 PM
$PEN SQUEEZE CITY!!! En Fuego tmrw!!! Show me $275+… 🔥🔥🔥🔥🔥🔥🔥
0 · Reply
Subox
Subox Nov. 5 at 9:16 PM
$PEN great numbers as always
0 · Reply
Estimize
Estimize Nov. 5 at 4:00 PM
$PEN reports after the close, Estimize Consensus +0.04 EPS and +3.49M Revs compared to WS http://www.estimize.com/pen/fq3-2025?utm_content=
0 · Reply
123rs123
123rs123 Nov. 2 at 3:00 PM
$PEN will he $300 within a few months
0 · Reply
Looking4Bargain
Looking4Bargain Oct. 30 at 6:22 AM
$PEN terrible price action.. what happened?
0 · Reply
filmhero
filmhero Oct. 27 at 9:56 PM
$PEN why down after TCT I wonder?
1 · Reply